Health Economics›Ovarian cancer›Adjuvant therapy for early stage disease

Adjuvant therapy for early stage disease

Ovarian cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	~16.4 mo	~30.0 mo	~18	~R 18 445 PFS proxy · indirect	32
Carboplatin monotherapy Variant #01	—	R 535	21d	—	—	2	R 1 070 PFS proxy	2
Observation Partial	—	—	—	~20.4 mo	~38.6 mo	—	—	2

3 of 3 regimens shown